Monogram Health, a Tennessee-based company that sends clinicians into patients’ homes to manage chronic kidney disease and other conditions, has agreed to pay $2.4 million to resolve allegations that it submitted false diagnosis codes to raise its payments from the Medicare Advantage program. The Department of Justice announced the settlement on August 24 and updated it the following day. As with every False Claims Act settlement, the claims are allegations only; no court has determined that Monogram did anything wrong.
Four Specific Diagnosis Codes at the Center of the Case
Monogram provided in-home care to Medicare Advantage patients under contracts with several Medicare Advantage Organizations, the private insurers that manage Medicare Advantage plans. Those contracts paid Monogram more when its patients carried higher “risk scores” — a number CMS calculates from the diagnosis codes on file, meant to predict how expensive a patient’s care will be. Under the specific risk-sharing arrangement described by prosecutors, Monogram earned a bigger payment whenever a patient’s risk score rose, because the insurer itself was collecting more from CMS for that same patient — a structure the government says gave Monogram a direct financial reason to add diagnosis codes that made patients look sicker on paper than their charts actually supported.
According to the Justice Department’s announcement, the conduct at issue ran from January 1, 2021, through December 31, 2023, and involved four named diagnosis categories: protein-calorie malnutrition, substance use disorder, coagulation defects and related blood disorders, and angina pectoris, a form of chest pain linked to reduced blood flow to the heart. Prosecutors allege the codes in these four categories were not clinically accurate, were not supported by documentation in patients’ medical records, or did not actually affect the patient’s care, treatment, or management at the visit where they were recorded. Under CMS rules, a diagnosis only counts toward a patient’s risk score if it comes from a genuine face-to-face visit and actually shaped what the provider did for that patient — a bar meant to stop paperwork alone from generating bigger checks from the government.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
How a Physician’s Whistleblower Lawsuit Started the Case
Unlike a larger Medicare Advantage settlement announced two days later involving a different provider, Monogram’s case began with a whistleblower, not a self-disclosure. Dr. Ajay Gupta, a nephrologist who formerly worked for Monogram as a regional medical director, filed a qui tam lawsuit under the False Claims Act’s whistleblower provisions, captioned U.S. ex rel. Dr. Ajay Gupta v. Monogram Health Professional Services in the Central District of California. Under those provisions, a private individual can sue on behalf of the government and collect a share of whatever the government eventually recovers; Gupta is set to receive approximately $380,000 of the $2.4 million settlement.
Whistleblower cases like Gupta’s make up a large share of False Claims Act enforcement nationally. The Justice Department’s own fiscal year 2025 enforcement report counted 1,297 new qui tam lawsuits filed that year, a record, with successful whistleblowers typically collecting between 15% and 30% of the government’s recovery, and health care fraud accounting for more than $5.7 billion of the $6.8 billion the department recovered under the statute that year. Monogram received formal credit for cooperating with investigators once the suit was filed, which is a different form of credit than the self-disclosure discount a company earns by reporting itself before any lawsuit exists.
A Smaller Dollar Figure, but a Pattern Regulators Were Already Targeting
Monogram’s $2.4 million payment, which includes interest and roughly $1.4 million in restitution, is a fraction of the $541.5 million a separate Medicare Advantage provider agreed to pay days later for a similar type of allegation involving unsupported diagnosis codes. The size difference reflects the scope of each company’s business, not a different legal theory. Notably, two of Monogram’s four flagged categories — protein-calorie malnutrition and angina pectoris — are diagnoses CMS itself later targeted for removal from its newer risk-adjustment model, called V28, specifically because of unusually high “coding intensity” in Medicare Advantage relative to traditional Medicare for those same conditions. That timeline suggests Monogram’s alleged conduct fit a pattern regulators were already moving to close off industry-wide, not an isolated one-company scheme.
What It Means for Monogram’s Medicare Advantage Patients
The settlement does not change the in-home care Monogram patients currently receive, and it does not allege that any patient was harmed medically by the disputed codes — the allegation concerns billing accuracy, not treatment decisions. Patients enrolled in a Medicare Advantage plan that used Monogram as an in-home provider will not see a bill, refund, or change in benefits as a direct result of this settlement; the corrections happen between Monogram, the Medicare Advantage insurers, and CMS. Monogram also received formal cooperation credit under the Justice Department’s guidelines in Justice Manual Section 4-4.112, the same framework prosecutors cite when a company assists an investigation without having self-reported first. As with the larger Villages Health case, the dollar figure here measures a dispute over billing paperwork between a provider, insurers, and the government — not a change to the medical care a Medicare Advantage patient is entitled to receive.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
